Immuno-oncology
The drugmaker presented multiple posters of data for the recently reapproved BCMA-targeting antibody-drug conjugate at the just concluded ASH meeting.
Arcus is ending development of its TIGIT-targeted antibody domvanalimab after it was determined a Phase III study would not show a survival benefit in gastrointestinal cancers.
J&J's late-breaking Phase III MajesTEC-3 data at the American Society of Hematology meeting highlighted curative potential for the bispecific T-cell engager in multiple myeloma.
To develop bispecific, dual-payload antibody-drug conjugates, Phrontline Biopharma’s strategy is to tune the activity of each payload to a similar level and engineer both toxins to fit within a branched linker, its CEO tells Scrip in an interview.
Next-gen CAR-T therapies showcased at the American Society of Hematology's annual meeting promise improved efficacy and safety, with Novartis, Gilead, and Kelonia advancing pivotal trials and exploring in vivo approaches.
The company presented data on four patients as a late-breaking abstract at the American Society of Hematology meeting.
The company presented positive efficacy and safety data from its registrational Phase II iMMagine-1 trial at the 2025 ASH meeting.
Janux wowed last year with first data from its ‘masked’ T-cell engager, JANX007, but investors have been spooked by newly updated results for the product. Analysts, however, still think it can compete with rivals from Amgen and J&J.
The company plans to take IGV-001 to the FDA after the mid-stage trial showed a more than six-month improvement in overall survival compared with placebo.
Akeso’s first-in-class PD-1/VEG-F bispecific ivonescimab is a landmark achievement for China’s biotech sector, but the firm is already expanding its ambitions in oncology and beyond, including a challenge to Roche in Alzheimer’s.
With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.
The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.
The agency’s approval of Imfinzi combined with chemotherapy makes it the only immunotherapy for perioperative gastric and gastroesophageal cancers.
Deal Snapshot: The US company has entered into another cancer drug transaction and bought Sprint's preclinical TREX1 program in a deal that could be worth around $400m.
The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.
Having built its reputation as the ‘Gateway to China’ for global firms, Zai is going global itself, moving its potential first-in-class ADC into Phase III development.
Terms like ‘game-changing’ and ‘transformational’ are regularly used by pharma companies but the data behind the latest approval for the Padcev/Keytruda combo for adults with muscle- invasive bladder cancer who are ineligible for cisplatin has been heralded by KOLs as exactly that.
Sichuan Biokin Pharmaceutical's BMS-partnered bispecific antibody-drug conjugate iza-bren had met both endpoints of PFS and OS in a China-only Phase III trial for the second-line treatment of esophageal squamous cell carcinoma.
The company announced topline results from its Phase III trial in gastroesophageal adenocarcinoma and plans to seek US FDA approval in the first half of 2026.
The German company is on a roll, early data on a pair of new T cell receptors adding to its promising lead cell therapy which impressed at ESMO.